MX2022000050A - Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet). - Google Patents

Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).

Info

Publication number
MX2022000050A
MX2022000050A MX2022000050A MX2022000050A MX2022000050A MX 2022000050 A MX2022000050 A MX 2022000050A MX 2022000050 A MX2022000050 A MX 2022000050A MX 2022000050 A MX2022000050 A MX 2022000050A MX 2022000050 A MX2022000050 A MX 2022000050A
Authority
MX
Mexico
Prior art keywords
heterocyclic compounds
bet inhibitors
inhibitors
bet
novel
Prior art date
Application number
MX2022000050A
Other languages
English (en)
Inventor
Sarvajit Chakravarty
Son Minh Pham
Jiyun Chen
Jayakanth Kankanala
Anup Barde
Anjan Kumar Nayak
Jeremy D Pettigrew
Chris P Miller
Original Assignee
Nuvation Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvation Bio Inc filed Critical Nuvation Bio Inc
Publication of MX2022000050A publication Critical patent/MX2022000050A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se proporcionan nuevos inhibidores de bromodominio y dominio extraterminal (BET) y métodos terapéuticos para tratar afecciones y enfermedades utilizando estos nuevos inhibidores de BET.
MX2022000050A 2019-07-02 2020-07-01 Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet). MX2022000050A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962870020P 2019-07-02 2019-07-02
US202063017547P 2020-04-29 2020-04-29
PCT/US2020/040566 WO2021003310A1 (en) 2019-07-02 2020-07-01 Heterocyclic compounds as bet inhibitors

Publications (1)

Publication Number Publication Date
MX2022000050A true MX2022000050A (es) 2022-05-24

Family

ID=74065335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000050A MX2022000050A (es) 2019-07-02 2020-07-01 Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).

Country Status (12)

Country Link
US (2) US11584756B2 (es)
EP (1) EP3997070A4 (es)
JP (1) JP7465945B2 (es)
KR (1) KR20220028072A (es)
CN (1) CN114286818A (es)
AU (1) AU2020299592A1 (es)
BR (1) BR112021026668A2 (es)
CA (1) CA3145827A1 (es)
CL (1) CL2021003513A1 (es)
IL (1) IL289439A (es)
MX (1) MX2022000050A (es)
WO (1) WO2021003310A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115716827A (zh) * 2018-07-25 2023-02-28 正大天晴药业集团股份有限公司 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途
EP3873474A4 (en) 2018-10-30 2022-07-13 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS BET Inhibitors
EP4143166A1 (en) * 2020-04-29 2023-03-08 Nuvation Bio Inc. Heterocyclic compounds as bet inhibitors
WO2023275542A1 (en) 2021-06-29 2023-01-05 Tay Therapeutics Limited Pyrrolopyridone derivatives useful in the treatment of cancer
CN116135858A (zh) * 2021-11-16 2023-05-19 中国科学院广州生物医药与健康研究院 一种呋喃并吡啶酮类化合物及其应用
TW202334148A (zh) * 2022-01-06 2023-09-01 美商規劃醫療公司 用於治療弗里德希氏共濟失調（ｆｒｉｅｄｒｅｉｃｈ＇ｓ ａｔａｘｉａ）之化合物及方法
CN114907335A (zh) * 2022-02-25 2022-08-16 陕西维世诺新材料有限公司 2-（苯并噻吩-2-基）苯并[d]惡唑衍生物、制备方法及应用
CN115028646B (zh) * 2022-05-31 2023-06-30 山东第一医科大学(山东省医学科学院) 一种含氮杂环类化合物、制备方法及在抗肿瘤制剂中的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118631A (en) 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
US20040067955A1 (en) 2002-09-06 2004-04-08 Fujisawa Pharmaceutical Co. Ltd. Pyridazinone compound and pharmaceutical use thereof
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
AU2007257922A1 (en) * 2006-06-08 2007-12-21 Eli Lilly And Company Novel MCH receptor antagonists
EP2214667A2 (en) 2007-10-22 2010-08-11 Angion Biomedica Corp. Small molecule inhibitors of parp activity
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2014078257A1 (en) * 2012-11-14 2014-05-22 Glaxosmithkline Llc Thieno[3,2-c]pyridin-4(5h)-ones as bet inhibitors
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
WO2014134267A1 (en) 2013-02-27 2014-09-04 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
CA2903463A1 (en) 2013-03-11 2014-10-09 The Regents Of The University Of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
US9050346B2 (en) * 2013-03-11 2015-06-09 Abbvie Inc. Bromodomain inhibitors
KR102224992B1 (ko) 2013-03-12 2021-03-10 애브비 인코포레이티드 테트라사이클릭 브로모도메인 억제제
AU2014230816B9 (en) 2013-03-14 2016-12-15 Glaxosmithkline Intellectual Property (No.2) Limited Furopyridines as bromodomain inhibitors
PE20151596A1 (es) 2013-03-14 2015-11-24 Glaxosmithkline Intellectual Property N 2 Ltd Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina 2,3-disustituidos y su uso como inhibidores del bromodominio
CN109939113B (zh) 2013-06-21 2022-02-15 恒翼生物医药科技(上海)有限公司 双环溴结构域抑制剂
MX2015017963A (es) 2013-06-28 2016-11-10 Abbvie Inc Inhibidores de bromodominio.
AU2014337064B2 (en) 2013-10-18 2019-03-14 Celgene Quanticel Research, Inc. Bromodomain inhibitors
WO2015074081A1 (en) 2013-11-18 2015-05-21 Bair Kenneth W Benzopiperazine compositions as bet bromodomain inhibitors
EP3071203B1 (en) 2013-11-18 2020-12-23 Forma Therapeutics, Inc. Tetrahydroquinoline compositions as bet bromodomain inhibitors
WO2015099107A1 (ja) 2013-12-26 2015-07-02 塩野義製薬株式会社 含窒素６員環誘導体およびそれらを含有する医薬組成物
SI3092227T1 (sl) 2014-01-09 2018-10-30 Orion Corporation Biciklični heterociklični derivati kot zaviralci bromodomaina
US9580430B2 (en) 2014-02-28 2017-02-28 The Regents Of The University Of Michigan 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
BR112016024626B1 (pt) 2014-04-23 2023-03-21 Incyte Holdings Corporation Compostos 1h-pirrolo[2,3-c]piridin-7(6h)-onas e pirazolo[3,4-c]piridin-7 (6h)-onas, uso dos mesmos, composição farmacêutica que os compreende e método de inibição de uma proteína bet
MA40366A (fr) 2014-09-12 2017-07-19 Glaxosmithkline Ip No 2 Ltd Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
US10307407B2 (en) 2015-02-27 2019-06-04 The Regents Of The University Of Michigan 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
CN107709298A (zh) 2015-06-16 2018-02-16 奥赖恩公司 作为溴结构域抑制剂的螺[环丁烷‑1,3’‑二氢吲哚]‑2’‑酮衍生物
MY195977A (en) 2015-09-21 2023-02-27 Plexxikon Inc Heterocyclic Compounds and uses Thereof
US10370356B2 (en) 2015-09-22 2019-08-06 Glaxosmithkline Intellectual Property (No. 2) Limited Pyridinone dicarboxamide for use as bromodomain inhibitors
ES2909122T3 (es) 2015-11-09 2022-05-05 Forge Therapeutics Inc Compuestos a base de hidroxipiridinona e hidroxipirimidinona para el tratamiento de infecciones bacterianas
CA3007168A1 (en) 2015-12-14 2017-06-22 Zenith Epigenetics Ltd. 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors
CR20180541A (es) 2016-04-15 2019-07-04 Abbvie Inc Inhibidores de bromodominios
EP3445750A4 (en) 2016-04-18 2019-11-27 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
US11285218B2 (en) 2016-06-23 2022-03-29 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use
CN108069958A (zh) 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用
CN110167939B (zh) 2017-01-11 2021-12-31 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用
IL275478B1 (en) 2017-12-20 2024-02-01 Betta Pharmaceuticals Co Ltd A preparation that functions as a bromodomain protein inhibitor, and the composition
WO2019141131A1 (zh) 2018-01-16 2019-07-25 中国科学院上海药物研究所 溴结构域抑制剂化合物及其用途
CN110041253B (zh) 2018-01-17 2022-03-29 上海翰森生物医药科技有限公司 吡啶类n-氧化衍生物及其制备方法和应用
CN115716827A (zh) 2018-07-25 2023-02-28 正大天晴药业集团股份有限公司 作为溴区结构域蛋白抑制剂的亚氨基砜类化合物、药物组合物及其医药用途
WO2020063976A1 (zh) 2018-09-29 2020-04-02 如东凌达生物医药科技有限公司 一类稠杂环联芳基苄醇类化合物、制备方法和用途
EP3873474A4 (en) 2018-10-30 2022-07-13 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS BET Inhibitors
WO2020160193A2 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
CN111704610B (zh) 2019-03-17 2022-03-22 上海凌达生物医药有限公司 一类吡咯酰胺并吡啶酮类化合物、制备方法和用途
WO2020253711A1 (zh) 2019-06-17 2020-12-24 中国科学院上海药物研究所 一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途
EP4143166A1 (en) 2020-04-29 2023-03-08 Nuvation Bio Inc. Heterocyclic compounds as bet inhibitors

Also Published As

Publication number Publication date
WO2021003310A1 (en) 2021-01-07
JP7465945B2 (ja) 2024-04-11
CA3145827A1 (en) 2021-01-07
JP2022538917A (ja) 2022-09-06
US11584756B2 (en) 2023-02-21
CN114286818A (zh) 2022-04-05
US20230339964A1 (en) 2023-10-26
CL2021003513A1 (es) 2022-10-28
US20210002293A1 (en) 2021-01-07
BR112021026668A2 (pt) 2022-02-15
AU2020299592A1 (en) 2022-02-17
KR20220028072A (ko) 2022-03-08
EP3997070A4 (en) 2023-07-26
EP3997070A1 (en) 2022-05-18
IL289439A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
MX2022000050A (es) Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).
PH12020550857A1 (en) Polycyclic compounds as allosteric shp2 inhibitors
MX2023004037A (es) Compuestos biciclicos como inhibidores alostericos de shp2.
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
WO2018136264A9 (en) Pyridine compounds as allosteric shp2 inhibitors
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
CR20200362A (es) CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395)
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
MX2022007376A (es) Fluoroalqull-oxadiazoles y sus usos.
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
EA201591382A1 (ru) Ингибиторы гистондеметилаз
MX2016010504A (es) Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas.
EA201590941A1 (ru) Гетероциклические ингибиторы глютаминазы
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
MX2017015740A (es) Moduladores de ror gamma (ror?).
EA201790907A1 (ru) Новые производные пиразолопиримидина в качестве ингибиторов nik
MX2023010429A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).
MX2021010916A (es) Inhibidores rad51.
MX2022000845A (es) Compuestos inhibidores.
MX2021012418A (es) Compuestos heterociclicos y sus usos.